Novartis | NOVN - Ebit


Novartis reported $4.18B in EBIT for its fiscal quarter ending in March of 2026.





Ebit Change Date
AbbVie USD 4.73B 1.08B Mar/2026
Alcon AG USD 297M 20M Mar/2026
Almirall EUR 30.23M 12.8M Dec/2025
Amgen USD 3.83B 130M Mar/2026
AstraZeneca USD 7.11B 4.14B Mar/2026
Autolus Therapeutics Ltd USD -59.51M 12.95M Mar/2026
Bayer EUR 3.53B 2.42B Mar/2026
Biogen USD 514.3M 502.8M Mar/2026
Bristol-Myers Squibb USD 3.56B 90M Mar/2026
Eli Lilly USD 9.78B 792M Mar/2026
Fresenius EUR 713M 139M Dec/2025
Fresenius Medical Care EUR 268M 395M Mar/2026
Genmab DKK 260M 199M Dec/2025
Gilead Sciences USD 2.68B 284M Mar/2026
GlaxoSmithKline GBP 2.29B 856M Mar/2026
GRIFOLS EUR 249M 103.11M Mar/2026
Hikma Pharmaceutical USD 348M 31M Dec/2025
J&J USD 6.62B 1.51B Mar/2026
Lakefront Biotherapeutics EUR -63.7M 844.26M Mar/2026
Lonza CHF 673M 54M Jun/2025
Merck EUR 1.05B 572M Mar/2026
Merck USD -1.88B 8.12B Mar/2026
Novartis USD 4.18B 118M Mar/2026
Novartis USD 4.06B 413M Dec/2025
Novo Nordisk DKK 59.62B 27.24B Mar/2026
Orion EUR 114.8M 213.3M Mar/2026
Pfizer USD 4.99B 340M Mar/2026
Philips EUR 302M 417M Mar/2026
Recordati EUR 231.11M 47.11M Mar/2026
Regeneron Pharmaceuticals USD 744.8M 153.8M Mar/2026
Roche Holding CHF 9.56B 2.1B Dec/2025
Sanofi EUR 1.94B 239M Mar/2026
UCB EUR 1.29B 571M Dec/2025